The purpose of the study is to classify the plasma amino acid levels in dogs with various underlying liver diseases. Our long term goal is to use this information to help us screen dogs for the development of a potentially fatal disease known as hepatocutaneous syndrome.
Dogs presenting for a hepatic biopsy or a full autopsy that have a chronic history of liver enzyme elevations, defined as serum ALT or ALP values greater than two times the upper limit of normal on at least two serum chemistry profiles taken at least 4 weeks apart, will be considered for enrollment. Liver biopsy results will determine if the patient will be enrolled in the study.
Exclusion criteria will be history compatible with acute liver disease, primary biliary disease or round cell neoplasia as well as any dog receiving supplemental protein. Dogs less than 5 kg will be excluded due to volume of blood draw needed.
If the liver biopsy results meet the criteria for entry into the study and a diet history survey is completed, plasma samples will be batched and shipped for analysis to the Amino Acid Laboratory at the University of California to measure the level of 28 common amino acids. These results will be available to client once they are available.
Sample or Data Requirements
8ml of blood in a heparin tube and a urine sample (free catch is sufficient)
For questions regarding the clinical trial please email the clinical trials technician, Diane Welsh at: email@example.com
Is Your Pet Eligible?
If you believe that your pet may be eligible for this study, please complete our prescreening questionnaire for owners.
If you believe you have a patient who is eligible for this clinical trial study or you would like additional information from the Clinical Trials Office at the Cummings Veterinary Medical Center, complete a referring physician questionnaire.